

UC Irvine

ICTS Publications

Title

Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures

Permalink

<https://escholarship.org/uc/item/3sh015cw>

Journal

Nephrology Dialysis Transplantation, 29(8)

ISSN

0931-0509 1460-2385

Authors

Lau, W. L.
Kalantar-Zadeh, K.

Publication Date

2014-04-15

DOI

10.1093/ndt/gfu086

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures

Wei Ling Lau¹ and Kamyar Kalantar-Zadeh^{1,2}

¹Division of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine (UCI) School of Medicine, Orange, CA, USA and ²Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA, USA

Correspondence and offprint requests to: Kamyar Kalantar-Zadeh; E-mail: kkz@uci.edu

The story of alkaline phosphatase in the management of mineral and bone disorder (MBD) in patients with chronic kidney disease (CKD) is an interesting and educational part of the history of nephrology. Circulating alkaline phosphatase, a marker of bone turnover, was among the first bone markers used for the detection and management of ‘renal osteodystrophy’, a term previously used by clinicians and researchers since the 1970s. However, by the mid-1990s and early 2000s alkaline phosphatase fell out of favor, when commercial parathyroid hormone (PTH) assays become available. At the same time, the first Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines on CKD-MBD chose not to mention alkaline phosphatase, as target ranges were uncertain [1]. A rise in serum alkaline phosphatase, known as hyperphosphatemia or hyperphosphatasia, is an expected finding in progressive CKD with worsening kidney function [2]. Elevated serum alkaline phosphatase concentrations in CKD patients with otherwise intact liver and biliary systems usually result from excess of the bone isoforms of the enzyme [3–5]. Specific detection of the bone isoform may not have clinical utility, since it was found not to correlate with inflammation or mortality risk [6]. The recent data suggest that a rise in alkaline phosphatase in dialysis patients is associated with worsening bone mineral density [7], and worse responsiveness to erythropoiesis stimulating agents [8].

The existence of an incremental and strictly linear associations between higher serum alkaline phosphatase (>120 U/L) and worse mortality was reported first in hemodialysis patients [9, 10], and more recently in peritoneal dialysis patients [11] as well as in non-dialysis dependent CKD patients [12–14]. At least in dialysis patients, these findings are in sharp contradistinction to the mortality predictability of serum PTH, which has a U-shaped relationship in that both high and low PTH are associated with higher death risk [10]. Even more importantly, the alkaline phosphatase-death association persists even across different PTH strata including when PTH is <150 pg/mL [9, 10]. Interestingly, a low alkaline phosphatase level is associated with greater survival, a finding that appears to

question the harmfulness of adynamic bone disease. These studies suggest that alkaline phosphatase is more than a mere marker of high-turnover bone disease and may serve a reliable mortality predictor. Hence, modulating alkaline phosphatase via interventions such as improving CKD care, better dialysis treatment, or therapy with vitamin D agents or calcimimetics, may improve not only bone health but also survival of CKD patients.

Higher circulating alkaline phosphatase may increase hydrolysis of pyrophosphate [15, 16], which is a potent inhibitor of vascular calcification [17–19]. The modulatory effect of alkaline phosphatase on pyrophosphate could be the link as to why lower levels of the former are associated with an incremental drop in mortality [20]. Consistent with this notion, a recent epidemiologic study found that higher levels of alkaline phosphatase (and not PTH, calcium or phosphorus) were associated with coronary artery calcification in hemodialysis patients [21]. Higher alkaline phosphatase levels are also associated with lower 25(OH) vitamin D level [22–24], which is *per se* associated with increased mortality [25].

In this issue of *Nephrology Dialysis Transplantation*, Maruyama *et al.* [26] examined the baseline data in 185 277 prevalent hemodialysis patients in Japan and related them to 1-year mortality and incident hip fracture events through calendar year 2010. They found that patients in the highest quartile of serum alkaline phosphatase had 46% and 25% higher all-cause and cardiovascular death risk, respectively, as well as a 71% higher incidence of hip fracture events, than those within the lowest quartile [26]. Whereas the mortality predictability of alkaline phosphatase is a well-known finding, this is the first report of such an association in a large cohort of Japanese dialysis patients. It is important to note that Japanese dialysis patients have by far the best survival among all known dialysis patients in the world, usually <10% per year, when compared with European and US dialysis patients who have an annual mortality of 15–20% or higher [26]. Japan is also the nation with the longest life expectancy of 92 years. Maruyama *et al.* reported an annual mortality of 7.9% in their

national Japanese cohort of over 150 000 hemodialysis patients, once again confirming the consistency of survival superiority in Japanese dialysis patients.

An even more novel and clinically relevant finding by Maruyama *et al.* [26] is the association of high serum alkaline phosphatase with bone fracture. During 1-year follow-up 1586 patients, or ~1% of the national cohort, experienced a new hip fracture. The odds ratio of hip fracture was 1.71 with a 95% confidence interval of 1.33–2.18. This adds to the growing evidence that points to alkaline phosphatase as a circulating marker for hip fracture risk [27, 28]. That this finding comes from Japanese patients is even more important, since Japan is one of the very few countries in the world that does not endorse or implement Kidney Disease Improving Global Outcomes (KDIGO) guidelines for CKD-MBD, which suggests a target PTH range of 150–600 pg/mL (2–9 times above the upper threshold); in Japan the target PTH range is 60–360 pg/mL [29]. Indeed, during the pre-KDIGO era, when the US KDOQI recommendations of 2002 suggested a PTH range of 150–300 pg/mL, Japan had an even lower target range of PTH of 60–180 pg/mL [29], a range that might be considered too low and a cause of adynamic bone disease by some West European and North American opinion leaders [29]. These low levels of PTH are usually achieved by administering high doses of active vitamin D, in particular maxacalcitol in Japan. Maxacalcitol is a vitamin D mimetic of D3 type with similarities to its D2 counterpart paricalcitol, which *per se* may be associated with survival advantages [30], when compared with other vitamin D analogs, including calcitriol (D3), 1-alpha (OH)-calciferol (D3) and 1-alpha-(OH)-ergocalciferol (D2), also known as doxercalciferol [31]. Whereas there are no clear data about the differential effect of these vitamin D analogs on PTH level or alkaline phosphatase, there is little doubt that all these agents [32], as well as calcimimetics [33], effectively lower alkaline phosphatase by ameliorating the activity of bone turnover.

Serum alkaline phosphatase is measured usually monthly to quarterly in all dialysis patients in most countries in the world and provides an excellent bone marker to monitor bone health in CKD, when compared with PTH which is a hormone from parathyroid glands, not bone, with only secondary impact on the bone. Hence, it is logical to use a direct bone marker rather than a non-bone-based hormone when the goal is to evaluate bone turnover. Given recent data that indicate a biologically plausible link between pyrophosphate degradation by tissue-non-specific alkaline phosphatase as a causative pathway in vascular calcification [15, 20], and given the lower bone density reported in dialysis patients with higher alkaline phosphatase levels [7], the data by Maruyama *et al.* [26] makes sense and is strong supportive evidence that alkaline phosphatase should be monitored more judiciously. High alkaline phosphatase levels of >120 IU/L has been suggested as a mortality cutoff by Regidor and colleagues [9]. The consistency of epidemiologic and experimental data on alkaline phosphatase and the effective lowering of alkaline phosphatase by vitamin D analogs and calcimimetics make this traditional marker a promising tool for the management of CKD-MBD, irrespective of the disappointing fact that current

KDOQI and KDIGO guidelines still have a major gap and disconnect from the data on alkaline phosphatase. There is prevailing concern with adynamic bone disease despite lack of epidemiological data to back this obsession. High-turnover bone disease, rather than adynamic bone disease, has clearly been associated with increased harm and may be a major culprit in the high death risk and hip fracture rate in dialysis patients. Measuring PTH and other circulating mineral markers without paying adequate attention to a marker that is truly of bone source, i.e. alkaline phosphatase, makes little sense; however, this unbalanced approach dominates current clinical practice. The recent data about the importance of alkaline phosphatase in dialysis patient outcomes are overwhelming [34–37]. We look forward to the needed heightened attention to serum alkaline phosphatase levels in the management of MBD in dialysis patients.

FUNDING

W.L.L. is supported by educational grants from Sanofi and Keryx. K.K.-Z. is supported by research grants from the NIH/NIDDK (R01-DK078106, K24-DK091419), and philanthropist grants from Mr Louis Chang and Mr Harold Simmons.

CONFLICTS OF INTEREST STATEMENT

W.L.L. has received grants from Sanofi and Keryx, and K.K.-Z. has received grants and/or honoraria from Abbvie, Amgen, Fresenius, Keryx, Shire and Vifor.

(See related article by Maruyama *et al.* A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. *Nephrol Dial Transplant* 2014; 29: 1532–1538.)

REFERENCES

1. National Kidney Foundation I, Kidney Disease-Dialysis Outcome Quality Initiative. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 2003; 42(Suppl 2): S1–S20
2. Reust CE, Hall L. Clinical inquiries. What is the differential diagnosis of an elevated alkaline phosphatase (AP) level in an otherwise asymptomatic patient? *J Fam Pract* 2001; 50: 496–497
3. Torres PU. Bone alkaline phosphatase isoforms in chronic renal failure. *Kidney Int* 2002; 61: 1178–1179
4. Jorge C, Gil C, Possante M *et al.* Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients—any advantage? *Nephron Clin Pract* 2005; 101: c122–c127
5. Kalantar-Zadeh K, Shah A, Duong U *et al.* Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. *Kidney Int Suppl* 2010; 117: S10–S21
6. Filipowicz R, Greene T, Wei G *et al.* Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. *Clin J Am Soc Nephrol* 2013; 8: 26–32
7. Park JC, Kovesdy CP, Duong U *et al.* Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. *Hemodial Int* 2010; 14: 182–192

8. Kalantar-Zadeh K, Lee GH, Miller JE *et al*. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. *Am J Kidney Dis* 2009; 53: 823–834
9. Kalantar-Zadeh K, Kuwae N, Regidor DL *et al*. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int* 2006; 70: 771–780
10. Regidor DL, Kovesdy CP, Mehrotra R *et al*. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. *J Am Soc Nephrol* 2008; 19: 2193–2203
11. Rhee CM, Molnar MZ, Lau WL *et al*. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. *Perit Dial Int* 2014 [Epub ahead of print]
12. Kovesdy CP, Ureche V, Lu JL *et al*. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. *Nephrol Dial Transplant* 2010; 25: 3003–3011
13. Taliercio JJ, Schold JD, Simon JF *et al*. Prognostic importance of serum alkaline phosphatase in CKD stages 3–4 in a clinical population. *Am J Kidney Dis* 2013; 62: 703–710
14. Beddhu S, Ma X, Baird B *et al*. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol* 2009; 4: 1805–1810
15. Lomashvili KA, Garg P, Narisawa S *et al*. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. *Kidney Int* 2008; 73: 1024–1030
16. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? *Kidney Int* 2008; 73: 989–991
17. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. *J Am Soc Nephrol* 2005; 16: 2495–2500
18. Lomashvili KA, Cobbs S, Hennigar RA *et al*. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. *J Am Soc Nephrol* 2004; 15: 1392–1401
19. Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. *Clin Sci* 1968; 35: 363–372
20. O'Neill WC. Pyrophosphate, alkaline phosphatase, and vascular calcification. *Circ Res* 2006; 99: e2
21. Shantouf R, Kovesdy CP, Kim Y *et al*. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. *Clin J Am Soc Nephrol* 2009; 4: 1106–1114
22. Lips P, Duong T, Oleksik A *et al*. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. *J Clin Endocrinol Metab* 2001; 86: 1212–1221
23. Sahota O, Masud T, San P *et al*. Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. *Clin Endocrinol (Oxf)* 1999; 51: 217–221
24. Thomas MK, Lloyd-Jones DM, Thadhani RI *et al*. Hypovitaminosis D in medical inpatients [see comments]. *N Engl J Med* 1998; 338: 777–783
25. Wolf M, Shah A, Gutierrez O *et al*. Vitamin D levels and early mortality among incident hemodialysis patients. *Kidney Int* 2007; 72: 1004–1013
26. Maruyama Y, Taniguchi M, Kazama JJ *et al*. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. *Nephrol Dial Transplant* 2014; 29: 1532–1538
27. Blayney MJ, Pisoni RL, Bragg-Gresham JL *et al*. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. *Kidney Int* 2008; 74: 655–663
28. Kaji H, Suzuki M, Yano S *et al*. Risk factors for hip fracture in hemodialysis patients. *Am J Nephrol* 2002; 22: 325–331
29. Qunibi W, Kalantar-Zadeh K. Target levels for serum phosphorus and parathyroid hormone. *Semin Dial* 2011; 24: 29–33
30. Miller JE, Molnar MZ, Kovesdy CP *et al*. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. *Pharmacoepidemiol Drug Saf* 2012; 21: 1232–1239
31. Park J, Rhee CM, Lau WL *et al*. Clinical uses of 1-alpha-hydroxy-ergocalciferol. *Curr Vasc Pharmacol* 2013 [Epub ahead of print]
32. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. *Clin J Am Soc Nephrol* 2009; 4: 1529–1539
33. Belozeroff V, Goodman WG, Ren L *et al*. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. *Clin J Am Soc Nephrol* 2009; 4: 673–679
34. Lukowsky LR, Molnar MZ, Zaritsky JJ *et al*. Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. *Nephrol Dial Transplant* 2012; 27: 2899–2907
35. Lertdumrongluk P, Lau WL, Park J *et al*. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. *Nephrol Dial Transplant* 2013; 28: 2535–2545
36. Li J, Molnar MZ, Zaritsky JJ *et al*. Correlates of parathyroid hormone concentration in hemodialysis patients. *Nephrol Dial Transplant* 2013; 28: 1516–1525
37. Lee GH, Benner D, Regidor DL *et al*. Impact of kidney bone disease and its management on survival of patients on dialysis. *J Ren Nutr* 2007; 17: 38–44

Received for publication: 16.3.2014; Accepted in revised form: 17.3.2014